Commonwealth Equity Services LLC Has $117,000 Holdings in GoodRx Holdings, Inc. (NASDAQ:GDRX)

Commonwealth Equity Services LLC decreased its holdings in shares of GoodRx Holdings, Inc. (NASDAQ:GDRX) by 30.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 25,216 shares of the company’s stock after selling 10,972 shares during the quarter. Commonwealth Equity Services LLC’s holdings in GoodRx were worth $117,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of the business. Barclays PLC grew its stake in shares of GoodRx by 1,316.1% during the 3rd quarter. Barclays PLC now owns 140,113 shares of the company’s stock worth $973,000 after acquiring an additional 130,219 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in GoodRx by 5.8% during the third quarter. Charles Schwab Investment Management Inc. now owns 480,123 shares of the company’s stock worth $3,332,000 after purchasing an additional 26,262 shares during the last quarter. IMC Chicago LLC acquired a new stake in GoodRx in the 4th quarter valued at $304,000. Franklin Resources Inc. acquired a new position in shares of GoodRx during the 3rd quarter worth about $5,675,000. Finally, Sanctuary Advisors LLC bought a new position in shares of GoodRx in the 3rd quarter valued at about $85,000. Institutional investors and hedge funds own 63.77% of the company’s stock.

GoodRx Stock Down 7.9 %

NASDAQ:GDRX opened at $4.32 on Friday. The company has a debt-to-equity ratio of 0.70, a current ratio of 5.48 and a quick ratio of 5.48. GoodRx Holdings, Inc. has a 1-year low of $3.82 and a 1-year high of $9.26. The company has a 50-day moving average of $4.66 and a 200 day moving average of $5.08. The firm has a market cap of $1.66 billion, a PE ratio of -144.00, a price-to-earnings-growth ratio of 2.46 and a beta of 1.25.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on the company. Truist Financial lowered their target price on GoodRx from $6.50 to $5.50 and set a “hold” rating on the stock in a research note on Thursday. Citigroup dropped their target price on GoodRx from $7.00 to $6.25 and set a “buy” rating for the company in a report on Friday, January 10th. KeyCorp reduced their target price on shares of GoodRx from $7.00 to $6.00 and set an “overweight” rating for the company in a research report on Wednesday, January 8th. Morgan Stanley lowered their price target on shares of GoodRx from $7.00 to $6.00 and set an “equal weight” rating on the stock in a research report on Tuesday, December 17th. Finally, Wells Fargo & Company cut their price objective on shares of GoodRx from $9.00 to $8.00 and set an “overweight” rating for the company in a report on Friday, February 28th. Four analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, GoodRx presently has a consensus rating of “Moderate Buy” and an average target price of $7.93.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.